(MTD) Mettler-Toledo International - Overview
Stock: Balances, Pipettes, Titrators, Weighing, Inspection
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 28.8% |
| Relative Tail Risk | -4.72% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.08 |
| Alpha | -16.33 |
| Character TTM | |
|---|---|
| Beta | 1.123 |
| Beta Downside | 1.110 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.81% |
| CAGR/Max DD | -0.08 |
Description: MTD Mettler-Toledo International December 17, 2025
Mettler-Toledo International Inc. (NYSE:MTD) designs, manufactures, and services precision weighing and analytical instruments across four geographic clusters (U.S., Swiss, Western Europe, China) plus a catch-all “Other” segment. Its product portfolio spans laboratory balances, pipetting and titration systems, real-time analytics, industrial scales, dimensional measurement tools, and AI-driven retail weighing solutions, all supported by software platforms such as LabX for data management.
Key recent metrics: FY 2023 revenue reached roughly $3.4 billion, with an operating margin of about 13 percent, and the laboratory-automation segment grew ~8 % YoY, outpacing the broader life-sciences tools sector. Primary economic drivers include sustained demand for clinical-diagnostics and biopharma R&D equipment (a post-COVID tailwind) and ongoing supply-chain pressure on semiconductor components that affect the company’s industrial-scale hardware. A sector-wide catalyst is the accelerating adoption of AI-enabled weighing and traceability solutions in food safety and logistics, which aligns with MTD’s retail-weighing product line.
If you want a concise, data-rich snapshot of MTD’s valuation and risk profile, the ValueRay platform provides a quick-look dashboard that can complement your analysis.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 869.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.23 > 0.02 and ΔFCF/TA -3.82 > 1.0 |
| NWC/Revenue: 4.09% < 20% (prev 0.66%; Δ 3.42% < -1%) |
| CFO/TA 0.26 > 3% & CFO 955.8m > Net Income 869.2m |
| Net Debt (2.09b) to EBITDA (1.24b): 1.68 < 3 |
| Current Ratio: 1.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (20.4m) vs 12m ago -3.41% < -2% |
| Gross Margin: 57.52% > 18% (prev 0.58%; Δ 5694 % > 0.5%) |
| Asset Turnover: 115.8% > 50% (prev 119.5%; Δ -3.69% > 0%) |
| Interest Coverage Ratio: 16.31 > 6 (EBITDA TTM 1.24b / Interest Expense TTM 68.5m) |
Altman Z'' 10.00
| A: 0.04 (Total Current Assets 1.36b - Total Current Liabilities 1.20b) / Total Assets 3.71b |
| B: 2.49 (Retained Earnings 9.24b / Total Assets 3.71b) |
| C: 0.32 (EBIT TTM 1.12b / Avg Total Assets 3.48b) |
| D: 2.38 (Book Value of Equity 8.88b / Total Liabilities 3.74b) |
| Altman-Z'' Score: 13.06 = AAA |
Beneish M -2.92
| DSRI: 1.09 (Receivables 778.2m/687.1m, Revenue 4.03b/3.87b) |
| GMI: 1.01 (GM 57.52% / 58.17%) |
| AQI: 1.03 (AQ_t 0.41 / AQ_t-1 0.39) |
| SGI: 1.04 (Revenue 4.03b / 3.87b) |
| TATA: -0.02 (NI 869.2m - CFO 955.8m) / TA 3.71b) |
| Beneish M-Score: -2.92 (Cap -4..+1) = A |
What is the price of MTD shares?
Over the past week, the price has changed by -0.87%, over one month by -6.25%, over three months by -4.12% and over the past year by +2.47%.
Is MTD a buy, sell or hold?
- StrongBuy: 4
- Buy: 0
- Hold: 9
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MTD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 1502.2 | 9.4% |
| Analysts Target Price | 1502.2 | 9.4% |
| ValueRay Target Price | 1372.4 | -0.1% |
MTD Fundamental Data Overview February 08, 2026
P/E Forward = 29.9401
P/S = 7.0272
P/B = 3980.9922
P/EG = 5.6789
Revenue TTM = 4.03b USD
EBIT TTM = 1.12b USD
EBITDA TTM = 1.24b USD
Long Term Debt = 2.15b USD (from longTermDebt, two quarters ago)
Short Term Debt = 63.9m USD (from shortTermDebt, last quarter)
Debt = 2.15b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.09b USD (from netDebt column, last quarter)
Enterprise Value = 30.38b USD (28.29b + Debt 2.15b - CCE 66.9m)
Interest Coverage Ratio = 16.31 (Ebit TTM 1.12b / Interest Expense TTM 68.5m)
EV/FCF = 35.80x (Enterprise Value 30.38b / FCF TTM 848.6m)
FCF Yield = 2.79% (FCF TTM 848.6m / Enterprise Value 30.38b)
FCF Margin = 21.08% (FCF TTM 848.6m / Revenue TTM 4.03b)
Net Margin = 21.59% (Net Income TTM 869.2m / Revenue TTM 4.03b)
Gross Margin = 57.52% ((Revenue TTM 4.03b - Cost of Revenue TTM 1.71b) / Revenue TTM)
Gross Margin QoQ = 56.27% (prev 59.19%)
Tobins Q-Ratio = 8.18 (Enterprise Value 30.38b / Total Assets 3.71b)
Interest Expense / Debt = 0.81% (Interest Expense 17.4m / Debt 2.15b)
Taxrate = 13.16% (43.3m / 329.1m)
NOPAT = 970.4m (EBIT 1.12b * (1 - 13.16%))
Current Ratio = 1.14 (Total Current Assets 1.36b / Total Current Liabilities 1.20b)
Debt / Equity = -91.05 (negative equity) (Debt 2.15b / totalStockholderEquity, last quarter -23.6m)
Debt / EBITDA = 1.68 (Net Debt 2.09b / EBITDA 1.24b)
Debt / FCF = 2.46 (Net Debt 2.09b / FCF TTM 848.6m)
Total Stockholder Equity = -178.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 25.00% (Net Income 869.2m / Total Assets 3.71b)
RoE = -487.2% (negative equity) (Net Income TTM 869.2m / Total Stockholder Equity -178.4m)
RoCE = 56.78% (EBIT 1.12b / Capital Employed (Equity -178.4m + L.T.Debt 2.15b))
RoIC = 50.38% (NOPAT 970.4m / Invested Capital 1.93b)
WACC = 9.39% (E(28.29b)/V(30.45b) * Re(10.05%) + D(2.15b)/V(30.45b) * Rd(0.81%) * (1-Tc(0.13)))
Discount Rate = 10.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -4.45%
[DCF Debug] Terminal Value 73.62% ; FCFF base≈855.0m ; Y1≈878.1m ; Y5≈980.7m
Fair Price DCF = 558.1 (EV 13.49b - Net Debt 2.09b = Equity 11.40b / Shares 20.4m; r=9.39% [WACC]; 5y FCF grow 2.67% → 2.90% )
EPS Correlation: 42.66 | EPS CAGR: 15.16% | SUE: 0.38 | # QB: 0
Revenue Correlation: 34.17 | Revenue CAGR: 6.32% | SUE: 1.26 | # QB: 3
EPS next Quarter (2026-03-31): EPS=8.73 | Chg30d=-0.225 | Revisions Net=+2 | Analysts=6
EPS current Year (2026-12-31): EPS=46.32 | Chg30d=+0.577 | Revisions Net=+1 | Growth EPS=+8.4% | Growth Revenue=+5.1%
EPS next Year (2027-12-31): EPS=50.89 | Chg30d=+0.211 | Revisions Net=+1 | Growth EPS=+9.9% | Growth Revenue=+4.5%